期刊文献+

肝外胆管癌中Ki-67表达及微血管密度与临床病理特征的关系 被引量:4

Relationship between expression of Ki-67,microvessel density and pathological characteristics in extrahepatic cholangiocarcinoma
下载PDF
导出
摘要 [目的]探讨肝外胆管癌中Ki-67表达和微血管密度与病理特征的关系.[方法]应用免疫组织化学SP法观察40例肝外胆管癌组织及10例癌旁黏膜组织标本中Ki-67表达,用CD 34抗体标记血管内皮细胞,并检测Ki-67标记指数和微血管密度,分析其与肝外胆管癌病理特征的相关性.[结果]肝外胆管癌组织中Ki-67标记指数为37.2%±5.1%,癌旁黏膜组织为8.9%±1.4%,差异具有统计学意义(P<0.05);肝外胆管癌中微血管密度值为56.5%±9.0%,癌旁黏膜组织中为20.6%±3.3%,差异亦具有统计学意义(P<0.05);Ki-67的标记指数和微血管密度与肝外胆管癌的分化程度、有无淋巴结转移及TNM分期均有明显相关性(P<0.05).肝外胆管癌组织中Ki-67标记指数与微血管密度呈正相关.[结论]Ki-67标记指数和肿瘤微血管密度与肝外胆管癌的病理特征密切相关,可作为评价肝外胆管癌生物学特性的指标. OBJECTIVE To study the relationship between expression of Ki-67,microvessel density(MVD) and pathological characteristics in extrahepatic cholangiocarcinoma(EHCC).METHODSExpression of Ki-67 and CD34 was detected by immunohistochemical SP method in 40 cases of EHCC and 10 cases of mucosa adjacent to EHCC.The labeling index(LI) of Ki-67 and MVD values were measured,and its correlation with the pathological characteristics of EHCC was analyzed.RESULTSThe LI of Ki-67 were 37.2%±5.1% and 8.9%±1.4%,and MVD values were 56.5%±9.0% and 20.6%±3.3%(P0.05) in EHCC and mucosa adjacent to EHCC,respectively.The LI of Ki-67 and MVD were related with differential degree,lymphnode metastasis and TNM stages of EHCC,and there was positive correlation between the LI of Ki-67 and MVD value.CONCLUSIONThe LI of Ki-67 and MVD are closely related with pathological characteristics in EHCC and the Ki-67 and MVD can be provide to target for judging biological characteristics of EHCC.
出处 《延边大学医学学报》 CAS 2011年第1期9-11,共3页 Journal of Medical Science Yanbian University
关键词 胆管肿瘤 KI-67抗原 抗原 CD34 微血管密度 bile duct neoplasms Ki-67 antigen antigens CD34 microvessel density
  • 相关文献

参考文献16

二级参考文献66

共引文献33

同被引文献23

  • 1黄志强.肝门部胆管癌外科治疗的现状与我见[J].中国实用外科杂志,2007,27(5):341-346. 被引量:78
  • 2李成刚,黄志强,韦立新,高丽杰,孟翔飞.肝门部胆管癌神经浸润特点的临床病理学分析[J].中华外科杂志,2007,45(15):1067-1068. 被引量:6
  • 3Weidner N. Current pathologic melhods for measuring intralumoral microvessel density within breast carcinoma and other solid tumors [ J ]. Breast Cancer Res Treat, 1995, 36 ( 2 ) : 169-180.
  • 4Gatto M, Alvaro D. Cholangiocarcinoma: risk factors and clinical presentation. Eur Rev Med Pharmacol Sci, 2010, 14 (4): 363 - 367.
  • 5Thelen A, Scholz A, Weichert W, et al. Tumor associated angiogen- esis and lymphoangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. Am J Gestroenterol, 2010, 105 ( 5 ) : 1123 - 1132.
  • 6Feisthammel J, Schoppmeyer K, M6ssner J, et al. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas : a multicenter phase II trial [ J ] . Am J Clin Oncol, 2007, 30 ( 3 ) : 319-324.
  • 7Gatto M, Alvaro D. Cholangiocarcinoma : risk factors and clinical presentation [ J ] . Eur Rev Med Pharmacol Sci, 2010, 14 (4) : 363-367.
  • 8Thelen A, Scholz A, Weichert W, et al. Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma [ J ] . Am J Gastroenterol, 2010, 105 (5): 1123-1132.
  • 9LaFemina J, Jarnagin WR. Surgical management of proximalbile duct cancers[J]. Langenbecks Arch Surg, 2012, 397(6):869-879.
  • 10Dobashi A,Imazu H,Tatsumi N,et al. Quantitative analysisof VEGF-C mRNA of extrahepatic cholangiocarcinoma with re-al-time PCR using samples obtained during endoscopic retro-grade cholangiopancreatography [ J ] . Scandinavian journal ofgastroenterology, 2013,48(7) . 848-855.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部